A randomized, double-blinded, parallel-group, vehicle controlled Phase II dose ranging trial of ATI-50002 Topical for the treatment of Alopecia Areata.
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2017
At a glance
- Drugs ATI 50002 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 11 Nov 2017 New trial record
- 07 Nov 2017 According to an Aclaris Therapeutics media release, data is expected to be available by year end of 2018.